MACCLESFIELD--21 Apr--PRNewswire-AsiaNet / InfoQuest
Cyprotex (AIM:CRX), the drug discovery technology and information company, is pleased to announce that it has received French research tax credit approval for years 2009 through to 2011.
The French Ministry of Research (Minist?re de l'Enseignement Sup?rieur et de la Recherche) has granted the French R&D tax credit ("Cr?dit d'Imp?t Recherche", CIR) accreditation to Cyprotex as of March 2010. This initiative allows eligible French pharmaceutical, biotech and agricultural companies subject to corporate tax in France, the ability to claim significant tax relief on costs generated in R&D requirements that are outsourced to Cyprotex Discovery.
Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments: 'We are delighted to receive this recognition and approval from the French Ministry of Research which will provide greater opportunities to support our current client base and allow for improved collaborations with future French clients.'
Additional information on the French research tax credit system is available from the Minist?re de l'Enseignement Sup?rieur et de la Recherche site - http://www.enseignementsup-recherche.gouv.fr/
For further information:
Cyprotex PLC
Dr. Anthony Baxter, Chief Executive Officer
Tel: +44-1625-505-100
[email protected]
http://www.cyprotex.com
Execution Noble & Company Limited
John Llewellyn-Lloyd
Sam Reynolds
Tel:+44(0)20-7456-9191
Public Relations
Financial Dynamics
Ben Brewerton
Ben Atwell
Mo Noonan
Tel: +44(0)20-7831-3113
SOURCE: Cyprotex
--Distributed by AsiaNet ( www.asianetnews.net )--